| 13.84 -0.3 (-2.12%) | 07-09 10:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.92 | 1-year : | 20.94 |
| Resists | First : | 15.35 | Second : | 17.92 |
| Pivot price | 12.65  |
|||
| Supports | First : | 11.35 | Second : | 8.89 |
| MAs | MA(5) : | 14.12 |
MA(20) : | 11.87 |
| MA(100) : | 9.41 |
MA(250) : | 8.58 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 80.9  |
D(3) : | 86.2 |
| RSI | RSI(14): 69.7 |
|||
| 52-week | High : | 15.35 | Low : | 6.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MGTX ] has closed below upper band by 22.4%. Bollinger Bands are 139.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 14.78 - 14.86 | 14.86 - 14.92 |
| Low: | 13.47 - 13.56 | 13.56 - 13.64 |
| Close: | 14.01 - 14.15 | 14.15 - 14.27 |
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Wed, 08 Jul 2026
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last? - Yahoo Finance
Wed, 08 Jul 2026
H.C. Wainwright reiterates MeiraGTx stock rating on financing deal - Investing.com
Wed, 08 Jul 2026
MeiraGTx Holdings (MGTX) Is Up 8.5% After Securing US$425M In New Funding Pathways – Has The Bull Case Changed? - simplywall.st
Wed, 08 Jul 2026
Insider Sell: Stuart Naylor Sells 27,659 Shares of MeiraGTx Holdings PLC (MGTX) - GuruFocus
Tue, 07 Jul 2026
Meiragtx chief scientific officer Naylor sells $409,470 in shares - Investing.com
Tue, 07 Jul 2026
MeiraGTx (MGTX) chief scientist sells 27,659 shares in pre-set 10b5-1 trades - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 5.226e+007 (%) |
| Held by Institutions | 17.8 (%) |
| Shares Short | 5,440 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.272e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -151.2 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 930.7 % |
| Return on Equity (ttm) | -28.1 % |
| Qtrly Rev. Growth | 7.976e+007 % |
| Gross Profit (p.s.) | -67.31 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 6.03889e+007 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -24.91 |
| Dividend | 0 |
| Forward Dividend | 5.55e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|